Savings Offer

$25 copy for up to a 60-day supply for eligible patients image

A 90-day supply will be prescribed to you as 3 bottles of 2.5 mL of solution each. The 90-day supply offer will only apply if each of the 2.5 mL bottles is covered by your commercial insurance.

 

Discounted pricing is available for eligible uninsured patients.
Ask your healthcare provider for more information about additional savings options.

*Eligibility Criteria/Terms and Conditions: By using the Bausch + Lomb Access coupon, you confirm that you understand and agree to comply with the following terms and conditions of this offer: This offer is only valid for eligible patients with commercial insurance and eligible uninsured patients. This offer is not valid for any person eligible for reimbursement of prescriptions, in whole or in part, by any federal, state, or other governmental programs, including, but not limited to, Medicare (including Medicare Advantage and Part A, B, and D plans), Medicaid, TRICARE, Veterans Administration or Department of Defense health coverage, CHAMPUS, the Puerto Rico Government Health Insurance Plan, or any other federal or state health care programs. Click here for full eligibility criteria.
Terms, conditions, and limitations apply. See eligibility criteria and terms and conditions at www.BauschAccessProgram.com.

Sign up to receive updates and learn more about VYZULTA

Sign up to receive updates and learn more about VYZULTA

By submitting your information you confirm you have read and agree with the terms of our Privacy Policy and Legal Notice.

By submitting your information you confirm you have read and agree with the terms of our Privacy Policy and Legal Notice.

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is used to lower intraocular (eye) pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Brown color, or increased brown color, of the iris can occur, which may be permanent. Darkening of the eyelid skin may also occur, which is usually reversible after VYZULTA treatment is discontinued.
  • Gradual changes to eyelashes may occur, including increased length, thickness, color, number of eyelashes and/or direction of eyelash growth. These changes may result in a difference in appearance of each eye. These changes are usually reversible after VYZULTA treatment is discontinued.
  • Avoid touching the tip of the container to the eye or any other surface, including a finger, in order to avoid contamination of the solution by bacteria. Serious damage to the eye and possible loss of vision may result from using contaminated solutions.
  • Tell your doctor immediately about any change in your eye, any eye condition that develops, any sudden change in your vision, any eye side effects, or if you have eye surgery.
  • Remove contact lenses before putting VYZULTA in your eyes. Lenses may be reinserted 15 minutes later.
  • If you are using other eye drops in addition to VYZULTA, wait 5 minutes between using each type of eye drop.
  • The most common side effects seen in studies were eye redness, eye irritation, eye pain, and pain after putting the drops in your eye.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

SEE MORE

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is used to lower intraocular (eye) pressure in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Brown color, or increased brown color, of the iris can occur, which may be permanent. Darkening of the eyelid skin may also occur, which is usually reversible after VYZULTA treatment is discontinued.